Send to printer »

Insight & Intelligence™ : Apr 18, 2014

Evolution of the Liquid Biopsies Space, Part One

This first in a series of reports on liquid biopsies looks at biomarker classes linked to that research space.
  • Enal Razvi, Ph.D.
  • ,
  • Gary Oosta, Ph.D.

The focus of this GEN Market & Tech Analysis report is to present some of our most recent analysis of publication trends across a number of biomarker classes with an eye toward categorizing them into segments especially as they relate to liquid biopsies.

Highlights:

  • This is the first report in a series of several to be published by GEN over the coming months focusing on the emerging and rapidly evolving field of liquid biopsies.
  • Focused herein are the various classes of circulating biomarkers, which provide the starting material for the development of liquid biopsies.
  • We’ve focused on circulating tumor cells (CTCs), circulating DNA, circulating RNA, and exosomes for the analysis presented herein.
  • These four analyte classes represent the current state of the art vis-à-vis circulating biomarkers, and there is much debate as to which marker[s] will provide prognostic and predictive utility across a wide swath of disease classes in the future—hence the vigorous research interest in all these spaces.